Non-Small Cell Lung Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Options by Stage
A link to a list of current clinical trials is included for each treatment section. For some types or stages of cancer, there may not be any trials listed. Check with your doctor for clinical trials that are not listed here but may be right for you.Occult Non-Small Cell Lung CancerTreatment of occult non-small cell lung cancer depends on the stage of the disease. Occult tumors are often found at an early stage (the tumor is in the lung only) and sometimes can be cured by surgery.Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with occult non-small cell lung cancer. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. General information about clinical trials is available from the NCI Web site.Stage 0 (Carcinoma in Situ)Treatment of stage 0 may include the following:Surgery (wedge resection or segmental
Small Cell Lung Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Options for Recurrent Small Cell Lung Cancer
Treatment of recurrent small cell lung cancer may include the following:Chemotherapy.Radiation therapy as palliative therapy to relieve symptoms and improve quality of life.Laser therapy, stent placement to keep airways open, and/or internal radiation therapy as palliative therapy to relieve symptoms and improve quality of life.Clinical trials of new chemotherapy treatments.Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with recurrent small cell lung cancer. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. General information about clinical trials is available from the NCI Web site.
Malignant Mesothelioma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Advanced Malignant Mesothelioma (Stages II, III, and IV)
Standard treatment options:Symptomatic treatment to include drainage of effusions, chest tube pleurodesis, or thoracoscopic pleurodesis. (Refer to the PDQ summary on Cardiopulmonary Syndromes for more information.)Palliative surgical resection in selected patients.[2,3]Palliative radiation therapy.[4,5]Single-agent chemotherapy. Partial responses have been reported with doxorubicin, epirubicin, mitomycin, cyclophosphamide, cisplatin, carboplatin, and ifosfamide.[6,7,8]Combination chemotherapy (under clinical evaluation).[6,7,9] Information about ongoing clinical trials is available from the NCI Web site. Multimodality clinical trials.[10,11,12,13]Intracavitary therapy. Intrapleural or intraperitoneal administration of chemotherapeutic agents (e.g., cisplatin, mitomycin, and cytarabine) has been reported to produce transient reduction in the size of tumor masses and temporary control of effusions in small clinical studies.[14,15,16] Additional studies are needed to define
Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment Option Overview for Small Cell Lung Cancer
Chemotherapy and radiation therapy have been shown to improve survival for patients with small cell lung cancer (SCLC).ChemotherapyChemotherapy improves the survival of patients with limited-stage disease (LD) or extensive-stage disease (ED), but it is curative in only a minority of patients.[1,2] Because patients with SCLC tend to develop distant metastases, localized forms of treatment, such as surgical resection or radiation therapy, rarely produce long-term survival. With incorporation of current chemotherapy regimens into the treatment program, however, survival is prolonged, with at least a fourfold to fivefold improvement in median survival compared with patients who are given no therapy. The combination of platinum and etoposide is the most widely used standard chemotherapeutic regimen.[4,5,6][Level of evidence: 1iiA] No consistent survival benefit has resulted from platinum versus nonplatinum combinations, increased dose intensity or dose density, altered mode of
Malignant Mesothelioma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - About This PDQ Summary
Purpose of This SummaryThis PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of malignant mesothelioma. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.Reviewers and UpdatesThis summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). Board members review recently published articles each month to determine whether an article should:be discussed at a meeting,be cited with text, orreplace or update an existing article that is already cited.Changes to the summaries are made through a consensus process
Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - nci_ncicdr0000062945-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Small Cell Lung Cancer Treatment
Important It is possible that the main title of the report Lymphangioleiomyomatosis is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report. ...
Small Cell Lung Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - To Learn More About Small Cell Lung Cancer
For more information from the National Cancer Institute about small cell lung cancer, see the following:Lung Cancer Home PageWhat You Need to Know About™ Lung CancerLung Cancer PreventionLung Cancer ScreeningDrugs Approved for Small Cell Lung CancerSmoking Home Page (Includes help with quitting)Cigarette Smoking: Health Risks and How to QuitSmoking in Cancer CareSecondhand Smoke and CancerFor general cancer information and other resources from the National Cancer Institute, see the following:What You Need to Know About™ CancerUnderstanding Cancer Series: CancerCancer StagingChemotherapy and You: Support for People With CancerRadiation Therapy and You: Support for People With CancerCoping with Cancer: Supportive and Palliative CareQuestions to Ask Your Doctor About CancerCancer LibraryInformation For Survivors/Caregivers/Advocates
Lung Cancer Prevention (PDQ®): Prevention - Health Professional Information [NCI] - Changes to This Summary (08 / 02 / 2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Description of the EvidenceAdded Spira et al. as reference 4.Added Lissowska et al. as reference 23.Added Straif et al. as reference 27.Added Gray et al. as reference 32.Added text evidence indicating an association between constituents of ambient air pollution and increased lung cancer mortality continues to strengthen, with reports from Asia and New Zealand documenting increased risks with exposure to measures of particulate matter, sulfur dioxide, and nitrogen dioxide (cited Katanoda et al., Cao et al., and Hales et al. as references 37, 38, and 39, respectively).Added World Cancer Research Fund/American Institute for Cancer Research as reference 40.This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary
Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Cellular Classification of Small Cell Lung Cancer
Before initiating treatment of a patient with small cell lung cancer (SCLC), an experienced lung cancer pathologist should review the pathologic material.Pathologic ClassificationThe current classification of subtypes of SCLC includes the following:Small cell carcinoma.Combined small cell carcinoma (i.e., SCLC combined with neoplastic squamous and/or glandular components).SCLC arising from neuroendocrine cells forms one extreme of the spectrum of neuroendocrine carcinomas of the lung.Neuroendocrine tumors include the following:Low-grade typical carcinoid.Intermediate-grade atypical carcinoid.High-grade neuroendocrine tumors including large-cell neuroendocrine carcinoma (LCNEC) and SCLC.Because of differences in clinical behavior, therapy, and epidemiology, these tumors are classified separately in the World Health Organization (WHO) revised classification. The variant form of SCLC called mixed small cell/large cell carcinoma was not retained in the revised WHO classification.